Growth momentum to continue in Q2, H2 due to trastuzumab launch, says Biocon

Biocon reported a good quarter with the company's biologics business growing quarter on quarter (QoQ) and margins come in-line. Kiran Mazumdar Shaw, CMD of Biocon shared her views and outlook.